 Clinical Oncology News | Clinical Hematologic Review: Highlights from ASH and NEJM, JCO and Blood Clinical Oncology News Investigators from MD Anderson Cancer Center presented encouraging Phase II data showing ibrutinib (PCI-32765, Janssen) in combination with rituximab to be safe and well tolerated with very high early response rates for patients with high-risk chronic ... |
